Diabetes news
2018-12-11
Omnipod GO Receives FDA Approval for Adults with Type 2 Diabetes
This FDA approval marks the first-of-its-kind of a basal-only tubeless insulin pod for adults with type 2 diabetes. MORE
Eli Lilly’s Baqsimi Acquired by Amphastar: What This Means for People With Diabetes
Eli Lilly’s nasal glucagon, Baqsimi, has been acquired by Amphastar. Here’s what you should know about the change and its significance.MORE
Mark Cuban’s Cost Plus Drugs Makes Diabetes Products More Affordable
Mark Cuban's Cost Plus Drugs Company just announced that they offer Janssen's Invokana, Invokamet and Invokamet XR for type 2 diabetes.MORE
California Partners with Civica Rx to Make More Affordable Insulin
California has signed a contract with Civica Rx to make more affordable insulin for Americans with diabetes. Here’s what you should know about their partnership, CalRx.MORE
Sanofi to Slash Price of Lantus by 78%, Cap Out-of-Pocket Costs to $35
Sanofi has capped monthly out-of-pocket costs for Lantus to $35 for all with commercial insurance and will cut the price of Lantus by 78%, effective January 1, 2024. MORE
Novo Nordisk to Slash Insulin Prices by over 65%
Novo Nordisk announced that starting January 1st, 2024 they will be lowering the list price of several of their insulins by 65-70%.MORE
$25 List Price + $35 Copay Caps: Lilly’s New Insulin Cost Reductions
On March 1, 2023, insulin manufacturer Lilly announced expanded insulin cost-saving measures for people with and without health insurance coverage.MORE
This New App is Designed to Make Tracking Your Insulin Easier
If you use Lilly brand insulin, this new connected platform is designed to make tracking your diabetes data a lot easier. MORE
Explore the Beyond Type 2 Community
Join the Beyond Type 2 Community, a safe space for those with type 2 diabetes to connect, share experiences, and get questions answered.MORE
Say Hello to BeyondType2.org in French, German and Italian!
BeyondType2.org now offers critical resources in five languages for people living with and impacted by type 2 diabetes.MORE
Congress Wants You to Know About These New, Cheaper Insulins
This legislation aims to help you and your doctor understand the potential benefits of cost-saving biosimiliar drugs and how to access them.MORE
Insulin Prices Are Rising Unchecked. New Biosimilar Insulins May Cost You Less.
You may soon be able to substitute newer, cheaper insulins that work exactly the same as your current prescription.MORE
Lilly to Discontinue Old School Glucagon Emergency Kit at End of 2022
With several modern and ready-to-use glucagon options available, Lilly will discontinue the old, red glucagon emergency kit in all markets. MORE
UnitedHealthcare Announces $0 Copay on Insulin, Glucagon + More, Beginning in 2023
UnitedHealthcare announced a $0 copay on insulin, glucagon and other drugs starting in 2023. Here's what that could mean for UHC members.MORE
New Program Offers $35 Monthly Copays for Sanofi Insulins
Sanofi has announced a $35 per month insulin copay program for uninsured individuals in the U.S, effective July 1, 2022.MORE
Type 2 Diabetes in Children + Teens: A History of Care + its Challenges
Understanding the unique challenges for young people with type 2 diabetes and their families can improve care and education. MORE
Year in Review: The Biggest News in Diabetes Clinical Science
Highlights from the last year of diabetes research and treatment include new biosimilar insulins and updated screening and diagnosis guidelines.MOREResearch: Practical Use of Closed-Loop Insulin Pumps
Closed-loop insulin pump technology is a game-changer for those taking insulin. Here are essential tips to using them in day-to-day life.MOREWeight Management + Type 2 Diabetes: Using Compassion, Medicine and Surgery
Weight loss has several benefits for people with type 2 diabetes. However, it isn’t always easy to achieve through only lifestyle changes.MORE
The Future of Insulin—Will It Be Affordable for the People Who Need It?
Research is showing promising advancements with new weekly oral and injectable insulins—but will they actually be affordable?MOREDiabetes + Dementia: Using Nasal Insulin to Improve Brain Function
With rising rates of obesity in both type 1 and type 2 diabetes, understanding the impact on long-term brain health and function is critical.MORE
Researchers Talk: Past, Present and Future of Pancreas Transplants
Are pancreas transplants the way of the future for people with diabetes? Here’s what you should know about the procedure.MORENot All Net Carbs and Artificial Sweeteners are Alike
Experts discuss the complexities of how net carbs and artificial sweeteners affect everyone with diabetes differently. MOREYoung Adults with T1D + T2D Need Personalized Care
By understanding the unique challenges of early adulthood, providers can empower young adults with type 1 and type 2 diabetes.MORE
When is the Right Time to Eat with Diabetes?
Experts discuss if there’s an optimal way to time your meals and the common “3 meals and 3 snacks per day” rule. MOREType 2 Diabetes in Children + Teens: A History of Care + its Challenges
Understanding the unique challenges for young people with type 2 diabetes and their families can improve care and education. MOREReaching Everyone—Health Disparities in Physical Activity
People living with diabetes are told to just exercise more to better manage their diabetes. Here is why it's not that simple. MORERace, Racism, and Diabetes Research
Diabetes care and research is still drastically impacted by racist practices. It’s time to call the racism out. MOREChallenges + Solutions for Underserved Communities in East Los Angeles
People living with diabetes in East L.A. face many challenges in getting the care they need. Is Blue Circle Health a potential solution?MOREAddressing Social and Structural Health Inequities in Diabetes Care
To address long-standing health inequities, providers and health systems must engage with barriers to high-quality diabetes care.MOREThe Negative Impact of Diabetes Stigma: “Words create reality”
Key behavioral science research proves the impact of attitudes and words on people living with diabetes and why those stigmas must change.MOREWeight Bias + Diabetes: “Stigma does not motivate anyone”
In this coverage, we share research highlighting how weight bias affects people with diabetes and what can be done to change public attitudes.MOREMounjaro: Its Powerful Potential to Treat Type 2 Diabetes + Obesity
Experts discuss the impressive impact and future potential of using Mounjaro (tirzepatide) to treat obesity and type 2 diabetes.MOREDiabetes Standards of Care Updated for Preventing or Delaying Type 2 Diabetes
The ADA has updated the standards of care to include recommendations that focus on preventing or delaying type 2 diabetes and its associated complications.MOREAnother Reminder that Racial/Ethnic Inequality Exists in Diabetes Care
Despite the variety of diabetes medications and technology, race and ethnicity still weigh heavily on a person’s access to these life-saving tools.MOREAccess to Insulin: In the United States
Despite the growing variety of insulin and technology, access to this life-saving drug continues to be a dire problem in the United States.MOREAccess to Insulin: In Low-Income Countries
In many countries, a person with diabetes may walk for four days to get a vial of short-acting insulin and seven to 10 days for long-acting.MORE
Abbott’s Freestyle Libre 3 Receives FDA Approval
The Freestyle Libre 3, the world's smallest continuous glucose monitor, offering several improvements and updates from the Libre 2, has received FDA approval.MORE
Research Suggests Changing Treatment Approach for Type 2 Diabetes
With more medication and technology available for treating type 2 diabetes, it's about time more providers make better use of them. MORE
Mounjaro Shows Multiple Benefits for Type 2 Diabetes Management
New, FDA-approved Mounjaro shows promising results for improving several aspects of type 2 diabetes management. MORE
FDA Approves Lilly’s Mounjaro: First of its Kind Medication for Treatment of Type 2 Diabetes
The FDA approved Mounjaro from Lilly, the first GIP/ GLP-1 receptor agonist to treat people with type 2 diabetes. MORE
Promising New Drug Leads to 22.5% Weight Loss in Adults Living with Obesity
The latest study on a new drug is making headlines for its impressive ability to help patients lose weight.MORE
Despite Universal Healthcare, Diabetes Disparities Persists in the United Kingdom
To address the racial and economic divide in diabetes technology use, a top diabetes specialist urges a change in pump and CGM training.MORE
ATTD 2022 Coverage: Advanced Technologies + Treatments for Diabetes
ATTD's annual conference covers the latest in diabetes technology and treatment. This year's event is in Barcelona from April 27-30, 2022. MORE
Coverage of Dexcom G6 CGM Now Improved with TRICARE
TRICARE healthcare members can now receive the Dexcom G6 continuous glucose monitor (CGM) under pharmacy benefits.MORE
The Rise of Prediabetes Diagnoses
There has been an increase in the number of people diagnosed with prediabetes. We spoke with Dr. Mayer B. Davidson to learn why.MORE
Beyond Type 1 Names Deborah Dugan as New CEO
Global diabetes nonprofit Beyond Type 1 has announced the appointment of its new CEO Deborah Dugan, former CEO of (RED).MORE
A Second COVID-19 Booster Dose + The Latest Omicron Variant
Keeping up with the latest COVID-19 shot and variant news can be difficult. Here’s what you should know about Omicron XE and a second booster!MORE
A1c Test Results Are More Likely To Be Inaccurate for People Of Color–Here’s Why That Matters
A1c is one of the go-to tests for monitoring blood sugar, yet for people of African, South and Southeast Asian and Mediterranean ancestry, there’s a higher chance it’s not accurate.MORE
The Affordable Insulin Now Act: A Step Toward Federal Legislation
The Affordable Insulin Now Act, if passed in its current form, could help bring down the cost of insulin for millions of insured people with diabetes.MORE
FreeStyle Libre 2 Now More Easily Accessible for Military Members Through TRICARE
Military members with TRICARE now have easier access to Abbott’s FreeStyle Libre 2 continuous glucose monitor (CGM).MORE
Civica Rx Aims to Bring $30 Insulin to Market in 2024
Launching to market in 2024, Civica Rx aims to make insulin available for no more than $30 per vial, regardless of insurance status.MORE
COVID-19 Pushes FDA Approval of Breakthrough Device Designation for Dexcom CGM in Hospital Settings
The FDA has granted Breakthrough Device Designation for Dexcom CGM in hospital settings after the pandemic highlighted essential care needs for patients with diabetes.MORE
If You Take Insulin for Type 2 Diabetes, Your Doctor Should Also Prescribe This…
If you take insulin as a person with type 2 diabetes, your healthcare provider should prescribe emergency glucagon, too. Here’s why…MORE
Eversense E3 Continuous Glucose Monitor Gains FDA Approval, Offers Extended Wear-Time
The Eversense E3 continuous glucose monitor (CGM) is an exciting advancement for the diabetes community, with improved wear-time and accuracy.MORE
Inside the Drug Pricing Investigation from the House Oversight and Reform Committee
The results of the most recent report from the committee make things clear for the United States—the need for access to affordable healthcare is direr than ever.MORE
Mark Cuban’s New Online Pharmacy Provides Affordable Access to Some Common Prescription Drugs
Mark Cuban's latest investment in the pharmaceutical industry offers common generic prescription medications (not including insulin) at a fraction of the cost.MORE
Lilly Issues Voluntary Nationwide Recall of One Lot of Glucagon Emergency Kit
Lilly Diabetes announced the voluntary recall of lot D239382D, Expiration April 2022 of Glucagon Emergency Kits.MORE
The Latinx Diabetes Initiative Provides Culturally Tailored Care To Latinx Patients With Diabetes
Andreina Millan Ferro is centering culturally sensitive diabetes care for Latinx patients with diabetes at the Latinx Diabetes Initiative.MORE
All About Gvoke HypoPen®
Anyone who takes insulin and other medications that cause low blood sugar should know about the premixed insulin Gvoke HypoPen.MORE
Empowering Youth Through Diabetes Education In Mexico
Yarishdy Mora is the director of the Youth Health Program for Project HOPE in Mexico. She creates platforms that help youth learn about diabetes. MORE
Overweight Adults to Now Be Screened for Type 2 Diabetes At 35
The U.S. Preventive Services Task Force now recommends overweight and obese adults to get screened for Type 2 diabetes at the age of 35.MORE
The 2021 Association of Diabetes Care and Education Specialists (ADCES) Virtual Conference
The Beyond Type 2 team covered the virtual 2021 ADCES Conference, covering the latest in diabetes education for the T2D community.MORE
Pandemic Homelessness Disproportionately Impacts People With Diabetes
An American Diabetes Association report found that pandemic homelessness hit people with diabetes 48 times harder.MORE
Youth with T2D Experience Long-Term Complications By Young Adulthood
Type 2 diabetes cases are rising in children and we're starting to learn they experience long-term complications by young adulthood. MORE
Abbott’s FreeStyle Libre 2 App Receives FDA Clearance
On August 2, 2021, the FDA approved the FreeStyle Libre 2 app for adults and children with diabetes, allowing user to access glucose readings directly from their iPhone.MORE
FDA Approves Senza®, Nevro’s High Frequency Spinal Cord Stimulation Therapy For PDN
The Senza System has been approved by the FDA for the treatment of chronic pain associated with painful diabetic neuropathy. MORE
Semglee Receives FDA Approval as First Interchangeable Biosimilar Insulin
Semglee becomes the first interchangeable biosimilar product for the treatment of Type 1 and Type 2 diabetes.MORE
Providing Culturally Sensitive LGBTQ+ Diabetes Health Care
Culturally sensitive LGBTQ+ diabetes health care can decrease stigma and advance diabetes care access for the LGBTQ community. MORE
FDA Approves Kerendia For The Treatment Of Type 2 Diabetes
Kerendia will be available in the U.S. immediately for the treatment of chronic kidney disease associated with Type 2 diabetes.MORE
Research on Pancreas Transplants in Type 1 and Type 2 Diabetes
Pancreas transplants are not an easy solution to type 1 or type 2 diabetes, but for some, they may be life-saving.MORE
Healthcare Providers Will No Longer Be Allowed to Issue “Surprise” Bills
Editor’s Note: People who take insulin require consistently affordable and predictable sources of insulin at all times. If you or a loved one are struggling to afford or access insulin, you can buil...MORE
Walmart Launches Lower-Cost Analog Insulin: ReliOn NovoLog
ReliOn NovoLog will be available at Walmart and Sam's Club pharmacies for $72.88 per vial and $85.88 per box of five FlexPens.MORE
Effects of Medicaid Coverage on the Diabetes Prevention Program in California
Obidiugwu K. Duru presents at the 81st ADA conference on how medicaid impacts the California Diabetes Prevention Program.MORE
News from DiabetesMine™ D-Data Exchange 2021
D-Data is the event, where attendees can discover, learn about, and try demos of new diabetes tech. Here is a recap of the sessions we attended at D-Data 2021.MORE
Zegalogue® Is Now Commercially Available in the United States
Zegalogue®, also known as dasiglucagon, is now commercially available in the U.S. for the treatment of severe hypoglycemia.MORE
Breaking News from ADA 2021
Breaking news from the biggest diabetes conference of the year - the American Diabetes Association's 81st Scientific Sessions.MORE
American Diabetes Association’s 81st Annual Scientific Sessions: #ADA2021
The biggest diabetes conference of the year is virtual for the second year + Beyond Type 2 is reporting live! Keep up with our coverage here. MORE
Medicare Loosens Restrictions On Continuous Glucose Monitor Coverage
Medicare revised its local coverage determination policy to remove requirements for continuous glucose monitor coverage.MORE
Over Insulin Pricing, Mississippi AG Sues Insulin Manufacturers and Pharmacy Benefit Managers
MS attorney general Lynn Fitch filed a lawsuit against PBMs & insulin manufacturers for allegedly working together to inflate insulin prices.MORE
Supreme Court Votes To Keep The ACA Intact
The Affordable Care Act (ACA) provides health care to millions of Americans. The Supreme Court voted 7-2 to keep the ACA intact.MORE
Omnipod 5 Pivotal Trial Data Published
Data from the pivotal trial shows that the Omnipod 5 improves time-in-range, and reduces HbA1c and mean glucose levels. MORE
ATTD 2021: Lessons About Diabetes During The COVID-19 Pandemic
ATTD 2021 took place from June 2-5. Dr. Irl Hirsch shares his lessons about diabetes during the COVID-19 pandemic.MORE
Breaking News From ATTD 2021
This year, ATTD 2021 will be held virtually where developers and clinicians will present their new diabetes technology and research.MORE
COVID Pandemic Leads to a Sharp Drop in A1c Testing
"We started getting a lot of referrals with really high A1cs in the double-digits,” says Jennifer Okemah, MS, RD, BCADM, CDCES, CSSDMORE
Researchers Find That CGMs Provide Insight On The Progression Of Type 2 Diabetes Among Hispanic Adults
Researchers break down the importance of CGMs in understanding diabetes and how to tackle accessibility barriers among Hispanic adults. MORE
Combating Bullying: How One Person With Diabetes Fought To Test Her Blood Sugar In The Workplace
Sheri Byrne shares her experience on how she fought workplace bullying due to diabetes and advocated for herself.MORE
Bigfoot Unity™ Diabetes Management System Receives The Green Light From The FDA
Bigfoot Unity™, a one-of-a-kind diabetes management system with smart pen caps received FDA approval on May 10, 2021 and will reach select diabetes clinics this spring. MORE
Asian Isn’t A Monolith: Why More Specific Data Matters in Diabetes Research
Data on how diabetes impacts specific ethnic groups could help us better support people within Asian American Pacific Islander communities.MORE
Diabetes + Ramadan: Here’s How a Few People Are Observing
People with diabetes face their own set of challenges when observing Ramadan. Two people with diabetes share their experiences. MORE
Chris Hahm’s Uphill Battle: The Severe Underfunding of AAPI Diabetes Research
H. Chris Hahm shares her challenges of conducting diabetes research focused on the AAPI community, research that is severely underfunded.MORE
Doctors Agree: They Need More Time with Type 2 Diabetes Patients
90% of doctors want more time with Type 2 diabetes patients and better communication between specialists regarding each patient.MORE
Two Pillars in the Diabetes Community Unite to Serve Millions Living with Diabetes
The partnership will feature combined resources, strategies, and tactics to better serve people living with type 1 diabetes, type 2 diabetes, and prediabetes.MOREPriyanka Chopra Jonas Joins the Board of Directors at Beyond Type 1
Priyanka Chopra Jonas brings energy and expertise to Beyond Type 1 as it initiates new efforts to serve the diabetes community globally.MORE
Inside the Senate Report on Rising Insulin Prices
A January 2021 Senate Finance Committee report dug into the rapidly increasing cost of insulin. Here, we summarize and explain their findings.MORE
What to Know About the 2021 Standards of Care for Type 2 Diabetes
It's important to know which guidelines doctors follow to develop your treatment plans. Here's what to know about the 2021 Standards of Care.MORE
Get the Facts on Insulin Pricing + The Presidential Transition
A flurry of misinformation is stoking fears that the Biden Admin paused or reversed a previous Trump Admin policy that lowered the price of insulin. MORE
New Year, New Administration: What’s Coming For US Healthcare Policy
With a new governmental administration, it is likely we will see notable and impactful movement in healthcare policy. What can we expect? MORE
Beyond Type 2 Celebrates Two Years, Launches New Community Platform
Today, global diabetes nonprofit Beyond Type 1 celebrates the two year anniversary of the launch of Beyond Type 2 - a digital platform for those impacted by Type 2 diabetes, available in English and S...MORE
Study Finds Lilly’s Tirzepatide Reduces A1C and Body Weight
After a 52-week treatment plan, a study conducted by Eli Lilly and Company found that their new medication tirzepatide significantly reduced A1C and body weight in adults with Type 2 diabetes.MORE
